Board of Trustees

Bryce Warren, PhD

Bryce Warren

Bryce Warren is Highline Sciences Chief Scientific Officer. He is the Chairman of the Scientific Review Program of the Society of Clinical Research Associates (SoCRA) where he has been President and a member of the Board of Directors.

In over 20 years of both pure science and clinical research experience, Dr. Warren’s laboratory interests have included: malignant bone tumors and other sarcomas (he served as the UAMS institutional Clinical Research Scientist for Sarcoma Alliance through Research Collaboration), new uses of cytokines IL-2, IL-6, and IL-12 as anti-neoplastic agents, B vitamin chemistry and degredative product assessments, protein stability regulation, cell surface marker mapping and related stereochemistry. Dr. Warren has experience in over 300 clinical research studies covering both adult and pediatric indications, some of which include: Cardiac and orthopedic devices, Langerhans cell histiocytosis, anti-emetics, immunosuppression, studies of hemophilia, thrombophilia and other bleeding disorders; and including extensive pediatric hematology and oncology clinical research experience.

Dr. Warren has served as the Children’s Oncology Group UAMS Clinical Research Lead and the lead Clinical Research Auditor. He is a member of multiple national and international research societies and he co-developed and served as the Director of Business for The Arkansas Center for Bleeding Disorders 340B Federal drug purchasing program.

Dr. Warren joined the Histiocytosis Association Board of Trustees in May of 2015, and currently serves as its Vice-Chairman.

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
US & Canada Toll-Free: 1-800-548-2758 
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 
Follow Me on Pinterest   

¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: Nosotros podremos responderle tan pronto nos sea possible. Gracias!